Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.
| Drug | TSG | SLP (drug target) | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | # |
|---|---|---|---|---|---|---|---|---|---|---|
| docetaxel, thalidomide | CREBBP | BCL2 | 4 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | CREBBP | ABL1 | 4 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | CREBBP | BCL2 | 4 | |||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | CREBBP | ABL1 | 4 | |||||||
| 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis | CREBBP | PDPK1 | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CREBBP | ABL1 | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CREBBP | EPHB4 | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CREBBP | PIK3CB | 3 | |||||||
| amg 193, docetaxel, comparator amg 193 test tablet | CREBBP | BCL2 | 3 | |||||||
| bms-986340, bms-936558-01, docetaxel | CREBBP | BCL2 | 3 | |||||||
| dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus | CREBBP | MTOR | 3 | |||||||
| everolimus | CREBBP | MTOR | 7 | |||||||
| regorafenib | CREBBP | ABL1 | 7 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | CREBBP | ABL1 | 2 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | CREBBP | BCL2 | 2 | |||||||
| alendronate, etidronate, ibandronate, risedronate, raloxifene | CREBBP | ESR2 | 2 | |||||||
| alvocidib, paclitaxel | CREBBP | BCL2 | 2 | |||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | CREBBP | BCL2 | 2 | |||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | CREBBP | ABL1 | 2 | |||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | CREBBP | EPHB4 | 2 | |||||||
| bryostatin 1, paclitaxel | CREBBP | BCL2 | 2 | |||||||
| btla inhibitor (js004), toripalimab, paclitaxel, cisplatin | CREBBP | BCL2 | 2 | |||||||
| capecitabine, docetaxel | CREBBP | BCL2 | 2 | |||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | CREBBP | PDPK1 | 2 | |||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | CREBBP | BCL2 | 2 | |||||||
| carboplatin, docetaxel | CREBBP | BCL2 | 2 | |||||||
| carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection | CREBBP | BCL2 | 2 | |||||||
| carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu | CREBBP | BCL2 | 2 | |||||||
| carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | CREBBP | BCL2 | 2 | |||||||
| carboplatin, paclitaxel, panitumumab, radiotherapy | CREBBP | BCL2 | 2 | |||||||
| carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 | CREBBP | BCL2 | 2 | |||||||
| carboplatin, paclitaxel, three-dimensional conformal radiation therapy | CREBBP | BCL2 | 2 | |||||||
| cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy | CREBBP | BCL2 | 2 | |||||||
| chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy | CREBBP | BCL2 | 2 | |||||||
| cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy | CREBBP | BCL2 | 2 | |||||||
| cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy | CREBBP | BCL2 | 2 | |||||||
| cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy | CREBBP | BCL2 | 2 | |||||||
| cisplatin, paclitaxel, surgical procedure, radiation therapy | CREBBP | BCL2 | 2 | |||||||
| cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study | CREBBP | MTOR | 2 | |||||||
| cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study | CREBBP | BCL2 | 2 | |||||||
| cpt- 11, cisplatin, celecoxib, radiation, surgery | CREBBP | PDPK1 | 2 | |||||||
| dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg | CREBBP | BCL2 | 2 | |||||||
| docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone | CREBBP | BCL2 | 2 | |||||||
| durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel | CREBBP | BCL2 | 2 | |||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | CREBBP | JAK2 | 2 | |||||||
| filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy | CREBBP | BCL2 | 2 | |||||||
| filgrastim, paclitaxel, topotecan hydrochloride | CREBBP | BCL2 | 2 | |||||||
| filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | CREBBP | BCL2 | 2 | |||||||
| gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy | CREBBP | BCL2 | 2 | |||||||
| ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib | CREBBP | JAK2 | 2 | |||||||
| irinotecan, docetaxel | CREBBP | BCL2 | 2 | |||||||
| melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells | CREBBP | CHRNA9 | 2 | |||||||
| melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells | CREBBP | CACNG1 | 2 | |||||||
| mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed | CREBBP | BCL2 | 2 | |||||||
| mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a | CREBBP | BCL2 | 2 | |||||||
| ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine | CREBBP | BCL2 | 2 | |||||||
| olaparib | CREBBP | PARP3 | 2 | |||||||
| onc-392, pembrolizumab, docetaxel | CREBBP | BCL2 | 2 | |||||||
| paclitaxel | CREBBP | BCL2 | 2 | |||||||
| pembrolizumab, paclitaxel | CREBBP | BCL2 | 2 | |||||||
| pembrolizumab, paclitaxel, docetaxel, irinotecan | CREBBP | BCL2 | 2 | |||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | CREBBP | BCL2 | 2 | |||||||
| pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography | CREBBP | BCL2 | 2 | |||||||
| ramucirumab, paclitaxel | CREBBP | BCL2 | 2 | |||||||
| regorafenib, laboratory biomarker analysis | CREBBP | ABL1 | 2 | |||||||
| temsirolimus | CREBBP | MTOR | 2 | |||||||
| temsirolimus, laboratory biomarker analysis | CREBBP | MTOR | 2 | |||||||
| bosutinib | CREBBP | ABL1 | 7 | |||||||
| entrectinib | CREBBP | JAK2 | 7 | |||||||
| ponatinib | CREBBP | ABL1 | 7 | |||||||
| ruxolitinib | CREBBP | JAK2 | 7 | |||||||
| tadalafil | CREBBP | PDE5A | 7 | |||||||
| 18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography | CREBBP | PARP3 | 1 | |||||||
| 5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) | CREBBP | BCL2 | 1 | |||||||
| 5-fluorouracil, docetaxel, oxaliplatin | CREBBP | BCL2 | 1 | |||||||
| 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, carboplatin, paclitaxel, neoadjuvant radiation | CREBBP | BCL2 | 1 | |||||||
| 5-fluoruracil, cisplatinum, docetaxel | CREBBP | BCL2 | 1 | |||||||
| 5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy | CREBBP | BCL2 | 1 | |||||||
| 7-hydroxystaurosporine, fluorouracil | CREBBP | PDPK1 | 1 | |||||||
| 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis | CREBBP | PDPK1 | 1 | |||||||
| aee788, everolimus | CREBBP | MTOR | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CREBBP | PARP3 | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CREBBP | ABL1 | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CREBBP | MTOR | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CREBBP | EPHB4 | 1 | |||||||
| afatinib, docetaxel, radiation therapy | CREBBP | BCL2 | 1 | |||||||
| afuresertib, nab paclitaxel, docetaxel, sintilimab | CREBBP | BCL2 | 1 | |||||||
| agent-797, botensilimab, balstilimab, ramucirumab, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| ak109, paclitaxel, paclitaxel, ak104 | CREBBP | BCL2 | 1 | |||||||
| aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim | CREBBP | IL2RB | 1 | |||||||
| aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation | CREBBP | IL2RB | 1 | |||||||
| aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation | CREBBP | BCL2 | 1 | |||||||
| aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy | CREBBP | IL2RB | 1 | |||||||
| aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes | CREBBP | IL2RB | 1 | |||||||
| aldesleukin, muromonab-cd3, therapeutic tumor infiltrating lymphocytes, conventional surgery | CREBBP | IL2RB | 1 | |||||||
| aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery | CREBBP | IL2RB | 1 | |||||||
| aldesleukin, therapeutic autologous lymphocytes, zoledronic acid | CREBBP | IL2RB | 1 | |||||||
| alpelisib, everolimus, exemestane | CREBBP | MTOR | 1 | |||||||
| alvocidib, docetaxel | CREBBP | BCL2 | 1 | |||||||
| andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| anetumab ravtansine, bevacizumab, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib | CREBBP | MTOR | 1 | |||||||
| ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine | CREBBP | EGLN1 | 1 | |||||||
| atezolizumab, 5-fluorouracil, calciumfolinat, oxaliplatin, docetaxel | CREBBP | BCL2 | 1 | |||||||
| atezolizumab, biospecimen collection, capecitabine, computed tomography, docetaxel, echocardiography, fluorouracil, leucovorin calcium, lymphadenectomy, magnetic resonance imaging, oxaliplatin, positron emission tomography, surgical procedure | CREBBP | BCL2 | 1 | |||||||
| atezolizumab, tiragolumab, paclitaxel, cisplatin, atezolizumab matching placebo, tiragolumab matching placebo | CREBBP | BCL2 | 1 | |||||||
| au-007, aldesleukin, avelumab | CREBBP | IL2RB | 1 | |||||||
| avelumab, irinotecan, paclitaxel, best supportive care (bsc) | CREBBP | BCL2 | 1 | |||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | CREBBP | DNMT1 | 1 | |||||||
| azd1775, olaparib | CREBBP | PARP3 | 1 | |||||||
| azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus | CREBBP | MTOR | 1 | |||||||
| azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus | CREBBP | BCL2 | 1 | |||||||
| bbi608, paclitaxel, placebo | CREBBP | BCL2 | 1 | |||||||
| bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | CREBBP | BCL2 | 1 | |||||||
| bethanechol | CREBBP | CHRM5 | 1 | |||||||
| bethanechol | CREBBP | CHRM4 | 1 | |||||||
| bethanechol, gemcitabine, nab-paclitaxel | CREBBP | CHRM5 | 1 | |||||||
| bethanechol, gemcitabine, nab-paclitaxel | CREBBP | CHRM4 | 1 | |||||||
| bevacizumab, cediranib, cediranib maleate, olaparib | CREBBP | PARP3 | 1 | |||||||
| bevacizumab, dasatinib, placebo | CREBBP | ABL1 | 1 | |||||||
| bevacizumab, dasatinib, placebo | CREBBP | EPHB4 | 1 | |||||||
| bevacizumab, docetaxel, oxaliplatin | CREBBP | BCL2 | 1 | |||||||
| bevacizumab, everolimus, octreotide acetate | CREBBP | MTOR | 1 | |||||||
| bevacizumab, temsirolimus | CREBBP | MTOR | 1 | |||||||
| biological ni-1801, ni-1801 in combination with anti-pd1 (pembrolizumab), ni-1801 in combination with paclitaxel, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | CREBBP | PIK3CB | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib | CREBBP | PARP3 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab | CREBBP | PARP3 | 1 | |||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | CREBBP | PIK3CB | 1 | |||||||
| biospecimen collection, computed tomography, endoscopic ultrasound, esophagogastroduodenoscopy, fluorouracil, hypofractionated radiation therapy, leucovorin calcium, oxaliplatin, positron emission tomography, survey administration, docetaxel | CREBBP | BCL2 | 1 | |||||||
| biospecimen collection, computed tomography, magnetic resonance imaging, nivolumab, paclitaxel, questionnaire administration, ramucirumab | CREBBP | BCL2 | 1 | |||||||
| biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration | CREBBP | PARP3 | 1 | |||||||
| biospecimen collection, electronic health record review, fentanyl citrate, propofol, questionnaire administration, sevoflurane, surgical procedure | CREBBP | SCN4A | 1 | |||||||
| biospecimen collection, lidocaine, resection | CREBBP | SCN4A | 1 | |||||||
| bl-b01d1, irinotecan, paclitaxel, docetaxel | CREBBP | BCL2 | 1 | |||||||
| bnt327 dose level 1 (dl1), bnt327 dose level 2 (dl2), etoposide, carboplatin, paclitaxel, topotecan | CREBBP | BCL2 | 1 | |||||||
| bortezomib, carboplatin, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| botensilimab, balstilimab, chloroquine phosphate, celecoxib | CREBBP | PDPK1 | 1 | |||||||
| cadonilimab, ak117, oxaliplatin, tegafur-gimeracil-oteracil potassium, docetaxel, 5-fluorouracil | CREBBP | BCL2 | 1 | |||||||
| cadonilimab, pulocimab, paclitaxel, placebo | CREBBP | BCL2 | 1 | |||||||
| cadonilimab, radiotherapy, carboplatin, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| camrelizumab, docetaxel, irinotecan | CREBBP | BCL2 | 1 | |||||||
| camrelizumab, irinotecan, paclitaxel, paclitaxel-albumin, docetaxel, anlotinib | CREBBP | BCL2 | 1 | |||||||
| camrelizumab, paclitaxel, cisplatin | CREBBP | BCL2 | 1 | |||||||
| camrelizumab, paclitaxel, cisplatin, radiotherapy | CREBBP | BCL2 | 1 | |||||||
| capecitabine, carboplatin, docetaxel, fluorouracil, hafnium oxide-containing nanoparticles nbtxr3, intensity-modulated radiation therapy, leucovorin, oxaliplatin, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| capecitabine, cisplatin, docetaxel, epirubicin hydrochloride, gemcitabine hydrochloride | CREBBP | BCL2 | 1 | |||||||
| capecitabine, docetaxel, fluorouracil, leucovorin, oxaliplatin, radiation therapy, surgical procedure | CREBBP | BCL2 | 1 | |||||||
| capecitabine, docetaxel, fluorouracil, oxaliplatin, radiation therapy, therapeutic conventional surgery | CREBBP | BCL2 | 1 | |||||||
| capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab | CREBBP | PARP3 | 1 | |||||||
| carboplatin, 3 dimensional conformal radiation therapy, propranolol, intensity modulated radiation therapy, paclitaxel | CREBBP | ADRB3 | 1 | |||||||
| carboplatin, 3 dimensional conformal radiation therapy, propranolol, intensity modulated radiation therapy, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| carboplatin, cisplatin, docetaxel, etoposide, pembrolizumab | CREBBP | BCL2 | 1 | |||||||
| carboplatin, computed tomography, fluorouracil, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel, pembrolizumab, positron emission tomography, radiation therapy, therapeutic conventional surgery | CREBBP | BCL2 | 1 | |||||||
| carboplatin, ganetespib, paclitaxel, radiation therapy | CREBBP | BCL2 | 1 | |||||||
| carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab | CREBBP | BCL2 | 1 | |||||||
| carboplatin, laboratory biomarker analysis, paclitaxel, wild-type reovirus | CREBBP | BCL2 | 1 | |||||||
| carboplatin, paclitaxel, azd1775 | CREBBP | BCL2 | 1 | |||||||
| carboplatin, paclitaxel, vadimezan | CREBBP | BCL2 | 1 | |||||||
| carboxyamidotriazole, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| catumaxomab, fluorouracil, leucovorin, oxaliplatin, docetaxel, fluorouracil, leucovorin, oxaliplatin, docetaxel | CREBBP | BCL2 | 1 | |||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | CREBBP | TP53 | 1 | |||||||
| celecoxib, cyclophosphamide, etoposide, thalidomide | CREBBP | PDPK1 | 1 | |||||||
| celecoxib, isotretinoin, temozolomide, thalidomide | CREBBP | PDPK1 | 1 | |||||||
| celecoxib, temozolomide, thalidomide, adjuvant therapy | CREBBP | PDPK1 | 1 | |||||||
| ceralasertib, olaparib, durvalumab | CREBBP | PARP3 | 1 | |||||||
| cetuximab (erbitux), paclitaxel, cisplatin, radiation | CREBBP | BCL2 | 1 | |||||||
| cetuximab, cisplatin, paclitaxel, radiation therapy | CREBBP | BCL2 | 1 | |||||||
| chemotherapy, cladribine, radiation therapy | CREBBP | PNP | 1 | |||||||
| chemotherapy, suramin | CREBBP | F2 | 1 | |||||||
| chlorpromazine, temozolomide, radiation therapy | CREBBP | ADRA1A | 1 | |||||||
| cisplatin, docetaxel, floxuridine, fluorouracil, leucovorin calcium, conventional surgery | CREBBP | BCL2 | 1 | |||||||
| cisplatin, docetaxel, fluorouracil, radiation therapy | CREBBP | BCL2 | 1 | |||||||
| cisplatin, docetaxel, gemcitabine hydrochloride | CREBBP | BCL2 | 1 | |||||||
| cisplatin, docetaxel, gemcitabine hydrochloride, irinotecan hydrochloride | CREBBP | BCL2 | 1 | |||||||
| cisplatin, irinotecan hydrochloride, paclitaxel, conventional surgery, radiation therapy | CREBBP | BCL2 | 1 | |||||||
| cisplatin, oxaliplatin, fluorouracil (5-fu), capecitabine, paclitaxel, tislelizumab, placebo | CREBBP | BCL2 | 1 | |||||||
| cisplatin, paclitaxel, 5-fu | CREBBP | BCL2 | 1 | |||||||
| cisplatin, paclitaxel, adjuvant therapy, radiation therapy | CREBBP | BCL2 | 1 | |||||||
| cisplatin, paclitaxel, brachytherapy, radiation therapy | CREBBP | BCL2 | 1 | |||||||
| cisplatin, paclitaxel, surgical procedure | CREBBP | BCL2 | 1 | |||||||
| cisplatin, paclitaxel, topotecan hydrochloride | CREBBP | BCL2 | 1 | |||||||
| cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab | CREBBP | PARP3 | 1 | |||||||
| conventional surgery, laboratory biomarker analysis, sorafenib tosylate, temsirolimus | CREBBP | MTOR | 1 | |||||||
| crenolanib, ramucirumab, paclitaxel | CREBBP | BCL2 | 1 | |||||||
| cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl | CREBBP | IL2RB | 1 | |||||||
| cytoreductive surgery, perifosine, temsirolimus | CREBBP | MTOR | 1 | |||||||
| dabigatran etexilate, warfarin | CREBBP | F2 | 1 | |||||||
| dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis | CREBBP | SERPINC1 | 1 | |||||||
| dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis | CREBBP | SELP | 1 | |||||||
| dalteparin, radiation therapy | CREBBP | SERPINC1 | 1 | |||||||
| dalteparin, radiation therapy | CREBBP | SELP | 1 | |||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | CREBBP | ABL1 | 1 | |||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | CREBBP | EPHB4 | 1 | |||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | CREBBP | ABL1 | 1 | |||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | CREBBP | EPHB4 | 1 | |||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | CREBBP | ABL1 | 1 | |||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | CREBBP | EPHB4 | 1 | |||||||
| dasatinib, mfolfox6 | CREBBP | ABL1 | 1 | |||||||
| dasatinib, mfolfox6 | CREBBP | EPHB4 | 1 |